EYE vs REGN · rev $437.3M vs P/E 14, rev $14.34B
National Vision Holdings Inc (EYE) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
National Vision Holdings Inc (EYE) is a specialty retail company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported EYE revenue for 2024-12-28 was $437.3M. Net income was -$28.6M. Revenue was down 3.2% from 2024-09-28 to 2024-12-28. EYE currently screens at market cap $1.93B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
EYE currently screens at market cap $1.93B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the EYE and REGN stock pages for the full models.
Not investment advice.